Search for
Menu
About
Overview
Impact
Partners
Team
Entrepreneurs
Industries
Internship Program
Innovation Center
Mentors
Corporates
Capital
Rev1 Capital
Funds
Rev1 Spark Grant
Portfolio
Resources
Blog
Entrepreneur Toolkit
Jobs
Events
Get Started
Home
Entrepreneurs
Rev1 Labs
Corporates
Capital
Portfolio
About
Team
Events
Jobs
Blog
Get Started
Search for
Myonexus Therapeutics Receives FDA Orphan Drug Designation for LGMD Type 2E Treatment
By
Rev1 Staff
on
04/30/2018
Myonexus Therapeutics Receives FDA Orphan Drug Designation for LGMD Type 2E Treatment
Myonexus Therapeutics Receives FDA Orphan Drug Designation for LGMD Type 2E Treatment